| Intravesical and systemic chemotherapy in the management of superficial bladder cancer. | |
| | |
MedLine Citation:
|
PMID: 6438857 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Before deciding to begin intravesical prophylaxis, the physician must categorize the patient with respect to the stage of the tumor and the multiplicity of lesions. This may require mucosal biopsies in order to determine whether the patient had unifocal or multifocal disease. Thiotepa, mitomycin C, and doxorubicin hydrochloride are discussed specifically and compared. |
| | |
Authors:
|
M S Soloway |
Related Documents
:
|
20733957 - Efficacy of bladder-preserving therapy for patients with t3b, t4a, and t4b transitional... 10524877 - Upper tract recurrences following radical cystectomy: an analysis of prognostic factors... 2509157 - Clinical significance of urine ferritin determination in urologic malignancies. 2294257 - Preoperative irradiation and radical cystectomy for stages t2 and t3 squamous cell carc... 3784987 - Squamous cell carcinoma of the thymus: a case report of rapid response to cyclophospham... 9259967 - Surgical management of thyroid cancer invading the airway. |
Publication Detail:
|
Type: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review |
Journal Detail:
|
Title: The Urologic clinics of North America Volume: 11 ISSN: 0094-0143 ISO Abbreviation: Urol. Clin. North Am. Publication Date: 1984 Nov |
Date Detail:
|
Created Date: 1984-12-31 Completed Date: 1984-12-31 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 0423221 Medline TA: Urol Clin North Am Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 623-35 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Topical Aged Antineoplastic Agents / administration & dosage*, adverse effects Biopsy Carcinoma, Transitional Cell / diagnosis Cisplatin / therapeutic use Cyclophosphamide / therapeutic use Doxorubicin / administration & dosage Endoscopy Female Humans Male Methotrexate / therapeutic use Mitomycin Mitomycins / administration & dosage Neoplasm Recurrence, Local Random Allocation Risk Thiotepa / administration & dosage Urinary Bladder / pathology Urinary Bladder Neoplasms / drug therapy* Vitamins / therapeutic use |
| Grant Support | |
ID/Acronym/Agency:
|
CA 15934/CA/NCI NIH HHS; CA 18643/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Mitomycins; 0/Vitamins; 15663-27-1/Cisplatin; 23214-92-8/Doxorubicin; 50-07-7/Mitomycin; 50-18-0/Cyclophosphamide; 52-24-4/Thiotepa; 59-05-2/Methotrexate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Independence of hypoxic death of inspiratory PCO2 in rats and fossorial mole rats.
Next Document: Nutritional assessment and therapy in advanced urothelial cancer.